Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Effects of Bezuclastinib on other drugs
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of Bezuclastinib on other drugs

1 evidence topic · 1 source

Drug interaction: PEAK Part 1

“Combination with bezuclastinib” (opens the source at this quote in a new tab)
“26% and 35% reduction in median and geometric mean steady state AUC (AUCss), respectively, of combined sunitinib + its active metabolite” (opens the source at this quote in a new tab)